title: Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma.
abstract: The definition of the role of positron emission tomography (PET) in peripheral T-cell lymphomas (PTCLs) is still under investigation. The purpose of the present observational retrospective study was to assess the early prognostic value of PET after the first three cycles of therapy (PET+3), evaluating visual data in de novo PTCL patients treated in first line with standard chemotherapy and followed by both PET and computed tomography scan. Of 27 PET+3-negative patients, 19 also had a negative PET at the end of treatment (PET+6), whereas 8 of 27 had a positive final one; 6 of 7 PET+3-positive patients had a positive PET+6, whereas only 1 patient had a negative PET+6. Estimated overall survival plotted according to PET+3 results showed 78.6% for negative patients and 21.4% for positive patients at 88.7 months with a significant difference. Patients with negative PET+3 had superior progression-free survival of 72.6% compared with 16.7% of PET+3-positive patients. At the time of this analysis, 17 of 19 (89.5%) patients with negative PET+3 are in continuous complete response (CCR) and only 1 of 7 (14.2%) patients with positive PET+3 is still in CCR. In conclusion, our results indicate that positive PET+3 is predictive of a worse outcome in PTCL, and this significant statistical difference between the two curves could be clinically informative. Larger and prospective studies and harmonization of PET reading criteria are needed.
authors.affiliation: Institute of Hematology "L. and A. Seràgnoli," Bologna, Italy.
authors.forename: Cinzia
authors.initials: C
authors.lastname: Pellegrini
authors.affiliation: Institute of Hematology "L. and A. Seràgnoli," Bologna, Italy.
authors.forename: Lisa
authors.initials: L
authors.lastname: Argnani
authors.affiliation: Institute of Hematology "L. and A. Seràgnoli," Bologna, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Broccoli
authors.affiliation: Institute of Hematology "L. and A. Seràgnoli," Bologna, Italy.
authors.forename: Vittorio
authors.initials: V
authors.lastname: Stefoni
authors.affiliation: Institute of Hematology "L. and A. Seràgnoli," Bologna, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Derenzini
authors.affiliation: Institute of Hematology "L. and A. Seràgnoli," Bologna, Italy.
authors.forename: Letizia
authors.initials: L
authors.lastname: Gandolfi
authors.affiliation: Institute of Hematology "L. and A. Seràgnoli," Bologna, Italy.
authors.forename: Beatrice
authors.initials: B
authors.lastname: Casadei
authors.affiliation: Institute of Hematology "L. and A. Seràgnoli," Bologna, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Maglie
authors.affiliation: Institute of Hematology "L. and A. Seràgnoli," Bologna, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Pileri
authors.affiliation: Institute of Hematology "L. and A. Seràgnoli," Bologna, Italy pierluigi.zinzani@unibo.it.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Complete response; Computed tomography scan; Peripheral T-cell lymphoma; Positron emission tomography; Progression-free survival